Sage shares skyrocket after FDA allows expediting development of depression drug
Shares of Sage Therapeutics (SAGE) rose nearly 6% before the bell today after the FDA allowed it to accelerate the development of the company’s experimental depression drug SAGE -217 that is intended to treat two types of depression.
Et reprehenderit consequuntur qui. Sit ut ducimus magni eaque. Iste qui autem maxime asperiores consectetur aut. Dolor quo sequi est omnis quia.
Quaerat impedit odit sunt mollitia id ut. Beatae quae in error unde ad voluptates id fugiat. In possimus tempora animi eos consequatur.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...